Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Pheochromocytoma and paraganglioma (PPGL), drawn from the whole corpus: 6 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No reliable predictor of metastasis at diagnosis: molecular classifiers and SDHB status are being validated.
Nothing recorded yet.
Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
Withdrawal of 131I-MIBG from the market left a gap that 177Lu-DOTATATE and alpha-emitters are filling.
Sequencing belzutifan, radioligand therapy and kinase inhibitors: no comparative data.
Lifelong surveillance burden for gene carriers, with children of SDHB carriers screened from early childhood.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 13 changes by month →When this page itself was last checked or edited.
Pheochromocytoma/paraganglioma
FDA, 14 May 2025, LITESPARK-015 cohort A1; first oral therapy for the disease.
Progression-free survival at 12 months 36 percent with sunitinib against 19 percent with placebo, meeting the primary endpoint of the first randomised trial in the disease.
Baudin and colleagues, Lancet: first randomised trial in metastatic PPGL.
Iobenguane scan-positive unresectable, locally advanced or metastatic phaeochromocytoma or paraganglioma in patients 12 and older (Azedra, high-specific-activity form; discontinued 2024)